Logo
faq question Joey Med

GLP-1s and Your Brain in 2026: What a Major New Science Review Says About Memory, Attention, and Dementia Risk

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
A new review in Science examines what GLP-1 drugs like semaglutide and tirzepatide may do for memory, attention, and dementia risk — and what the evidence actually shows patients so far.

A new review in Science examines what GLP-1 drugs like semaglutide and tirzepatide may do for memory, attention, and dementia risk — and what the evidence actually shows patients so far.

Overview

Most people who start semaglutide or tirzepatide are thinking about the scale, their blood sugar, or their heart. This month, one of the world's top scientific journals asked a different question: what are these drugs doing to the brain? In a new review published in Science, researchers from the University of Gothenburg and the University of Copenhagen pulled together the evidence on GLP-1 medications and cognition — memory, attention, planning, and long-term dementia risk. The picture that emerges is genuinely interesting: promising signals in some places, a high-profile disappointment in another, and a clear message about who might stand to benefit. Here's what the review found, and what it means if you're taking or considering a GLP-1.

What the New Science Review Actually Says

The review, titled "Obesity pharmacotherapies and cognition," was written at the invitation of the journal Science by a team including first author Stina Börchers and senior author Christoffer Clemmensen. It covers GLP-1 therapies like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), along with newer combination drugs that also target GIP, glucagon, and amylin pathways.

Two findings anchor the paper. First, animal studies consistently show that GLP-1 drugs can influence learning and memory — in rodents, researchers have reported effects on the hippocampus (the brain's memory center), increased growth of new neurons, lower levels of amyloid and tau (the proteins that accumulate in Alzheimer's disease), and reduced brain inflammation. Second, the human evidence is far less consistent. As the University of Gothenburg's announcement puts it, the drugs affect biological processes relevant to brain function, but whether that translates into real cognitive protection for patients is still an open question.

"We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities," Börchers said.

The Dementia Signal in Health Records

One of the most intriguing threads in the review comes from large analyses of patient health records. These studies have found that people with type 2 diabetes who were prescribed GLP-1 medications went on to develop dementia at lower rates than similar patients who weren't.

That's a real and repeated observation — but the authors are careful about what it can and can't tell us. Observational studies like these cannot prove the drugs caused the lower risk. People who get prescribed GLP-1s may differ in other ways: better access to care, more engaged providers, healthier baseline habits. What the health-record data does justify, the researchers argue, is running proper clinical trials that measure memory and attention from the first day of treatment — something obesity drug trials have rarely done.

The background context matters here. Midlife obesity and type 2 diabetes are both well-established risk factors for dementia later in life. So a drug class that treats both conditions is, at minimum, addressing known contributors to cognitive decline — even before any direct brain effect is considered.

Why the Alzheimer's Trials Fell Short

If GLP-1s might protect the brain, why not test one directly against Alzheimer's disease? Novo Nordisk did exactly that. The EVOKE and EVOKE+ trials enrolled 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to biomarker-confirmed Alzheimer's, and treated them with once-daily oral semaglutide or placebo over a planned two-year period.

The result, presented at the CTAD conference in December 2025, was a clear miss: semaglutide did not significantly slow clinical progression on the primary measure (a standard dementia rating scale called CDR-SB) in either trial, and secondary cognitive outcomes showed no meaningful difference. Notably, the drug did move several Alzheimer's-related biomarkers — with reductions of up to roughly 10% reported — but those biological changes didn't translate into measurable benefit for patients, and Novo discontinued the trials' planned extension phase.

The Science review authors offer a pointed interpretation: by the time someone has established Alzheimer's disease, with plaques and brain atrophy already in place, treatment may simply come too late. The failure in diagnosed Alzheimer's, they argue, doesn't rule out a protective effect earlier in life — in people whose brains are still healthy.

What This Means If You're Taking (or Considering) a GLP-1

For patients, the practical takeaways are more grounded than the headlines suggest.

The review notes that people with obesity or type 2 diabetes frequently show subtle, subclinical difficulties with attention, processing speed, working memory, and mental flexibility — problems often tied to the metabolic and vascular strain these conditions put on the brain. Because GLP-1 drugs improve exactly those metabolic and vascular factors, the authors suggest this is where cognitive benefits are most plausible: not curing dementia, but helping preserve everyday sharpness in people treated before problems take hold. That remains a hypothesis to be tested, not a proven effect — but it's a reason for cautious optimism if you're treating obesity now, in midlife, rather than waiting.

There's also a caution worth taking seriously. Rapid weight loss can mean losing muscle as well as fat, and in older or frail adults the authors warn this could impair physical function and offset any cognitive gains. That's consistent with what we've covered before on preserving muscle during GLP-1 treatment: adequate protein and resistance exercise aren't optional extras — they're part of doing this treatment right, especially past age 60.

Side Effects and Safety Still Come First

None of this changes the basics of GLP-1 treatment. The most common side effects remain gastrointestinal — nausea, vomiting, diarrhea, and constipation — which typically ease as your dose is titrated up gradually, and which can often be managed with anti-nausea support. These medications aren't appropriate for everyone: a personal or family history of medullary thyroid cancer or MEN2 syndrome, a history of pancreatitis, and pregnancy are among the key contraindications a provider will screen for. Whether a GLP-1 makes sense for you — and which one — is a decision to make with a licensed clinician who knows your full history, not something to guess at from headlines about brain benefits.

How to Get Started With JoeyMed

If you're ready to find out whether GLP-1 treatment fits your health goals, JoeyMed makes the process straightforward. Start with an online visit, and a licensed provider will review your health history, screen for contraindications, and build a plan around your goals — whether that's semaglutide or tirzepatide-based weight loss treatment, including high-dose options like Tirz HD, or a broader look at your wellness and longevity picture. Treatment ships discreetly to your door, and your provider stays available as your plan evolves. The brain science is still being written — but taking care of your metabolic health today is the step the evidence already supports.

GLP-1s and Your Brain in 2026: What a Major New Science Review Says About Memory, Attention, and Dementia Risk | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL